Skip to main content

Table 2 Baseline characteristics

From: A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis

Parameter

Treatment group (N = 14)

Placebo group (N = 14)

Age (years; Mean ± SD)

37.2 ± 9.40

45.8 ± 12.26

Gender (Male:Female)

9:5

11:3

Height (cm; Mean ± SD)

165.2 ± 7.06

168.4 ± 5.45

Weight (kg; Mean ± SD)

63.3 ± 8.59

68.0 ± 9.32

Asian Race (N)

14 (100%)

14 (100%)

KOH Smear positive

14 (100%)

14 (100%)

Fungal culture positive

14 (100%)

14 (100%)

Live spore count positive

14 (100%)

14 (100%)

Type of Tinea and causative organism

 Tinea cruris

5

1

  Epidermophyton floccosum

3

0

  Trichophyton violaceum

1

1

  Trichophyton rubrum

1

0

 Tinea corporis

2

4

  Epidermophyton floccosum

1

1

  Trichophyton violaceum

0

1

  Trichophyton rubrum

1

2

 Tinea pedis

2

4

  Epidermophyton floccosum

2

4

  Trichophyton violaceum

0

0

  Trichophyton rubrum

0

0

Causative organism for Onychomycosis

 Epidermophyton floccosum

1

2

 Trichophyton mentagrophytes

2

2

 Trichophyton rubrum

2

1

Severity score

 Tinea (Mean ± SD)

9.0 ± 0.5

8.9 ± 0.6

 Size of lesion in subjects with Tinea (cm; Mean ± SD)

13.3 ± 5.1

8.0 ± 1.4

 Onychomycosis (Mean ± SD)

3.0 ± 0.0

3.0 ± 0.0

 Surface area affected in Onychomycosis (%; Mean ± SD)

63.0 ± 4.5

66.0 ± 5.5

  1. SD Standard deviation, cm Centimetre, KOH Potassium hydroxide